For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
|Videos|July 2, 2014
The 4Kscore Test as a Predictor of High-Grade Prostate Cancer
Author(s)Raoul S. Concepcion, MD, FACS
Raoul S. Concepcion, MD, FACS, Urology Associates P.C., discusses the potential for the 4Kscore test as a predictor of high-grade prostate cancer.
Advertisement
Clinical Pearls
Raoul S. Concepcion, MD, FACS, Urology Associates P.C., discusses the potential for the 4Kscore test as a predictor of high-grade prostate cancer.
- There remains a need for a way for physicians to determine which prostate cancer patients need to be biopsied and if the detected tumor is high-grade.
- An early study of about 1000 patients analyzed the 4Kscore test in this space.
- The 4Kscore test, with certain limits, may be able to predict higher-grade cancers. This test could reduce the number of biopsies without missing a significant number of high-grade tumors.
Advertisement
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
3
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
4
Proton Therapy Does Not Improve Survival in Advanced HCC Trial
5